CENAPT - University of Illinois at Chicago

📕 Can Invalid Bioactives Undermine Natural-Product Based Drug Discovery


Tags: IMPs PAINS HTS false hit news
Bisson J, McAlpine JB, Friesen JB, Chen S, Graham J, Pauli GF
Journal of Medicinal Chemistry 59(5), 1671-1690 (2015)
DOI:10.1021/acs.jmedchem.5b01009
PMC:PMC4791574 [OpenAccess]

Abstract

TOC graphic of the imp paper

High-throughput biology contributed a wealth of data on chemicals including natural products (NPs). Recently, attention was drawn to certain predominantly synthetic compounds which are responsible for disproportionate percentages of hits but “false” actives. Spurious bioassay interference designated them as pan-assay interference compounds (PAINS). NPs lack comparable scrutiny, which this study aims to rectify. Systematic mining 80+-years of the phytochemistry and biology literature, using the NAPRALERT database, revealed that only 39 compounds cover the NPs most reported by occurrence, activity, and distinct activity. Over 50% are not explained by phenomena known for synthetic libraries, and all had manifold ascribed bioactivities, designating them as invalid metabolic panaceas (IMPs). Cumulative distributions of ~200,000 NPs uncovered that NP research follows power-law characteristics typical for behavioral phenomena. Projection into occurrence-bioactivity-effort space produces the hyperbolic Black Hole of NPs, where IMPs populate the high-effort base. Awareness of IMPs helps clearing the path to meaningful drug leads.